Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): David Conen Added: 2 years ago
ESC 2023 — Dr David Conen (McMaster University, CA) joins us onsite for a short interview focussing on the findings from the COP-AF trial (NCT03310125). COP-AF (Population Health Research Institute) aimed to assess if oral colchicine reduced the incidence of perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery. 3209… View more
Author(s): Matthew J Budoff Added: 1 year ago
ACC 2025 - Outcomes from colchicine in patients with stable coronary artery disease (CAD) shows significant plaque volume progression compared to placebo at one year.Dr Matthew Budoff (UCLA Medical Centre, Los Angeles, US) joins us onsite at ACC 2025 to discuss findings from the randomized, placebo-controlled, investigator-initiated EKSTROM trial (NCT06342609; Lundquist Institute for Biomedical… View more
Author(s): Michael Honigberg Added: 2 years ago
AHA 23 — Dr Michael Honigberg (Massachusetts General Hospital, US) highlights key 2023 cardiology updates, featuring novel data from AHA Scientific Sessions.Dr Honigberg provides commentary on the new SELECT trial outcomes and emphasises the incretin mimetic, semaglutide's role in cardiovascular medicine. He delves into lipid management with a focus on the CLEAR trial data and the incorporation… View more
Added: 9 months ago Source:  ESC Congress 2025 Scientific Programme
ESC Congress 2025 has released twenty-eight late-breaking trials and science sessions to be presented in August 2025.The congress is set to take place from the 29th August to 1st September at IFEMA - Fiera de Madrid.Access the full programme here.Late-Breaking Clinical Science: Inflammation and Immune Biomarkers in Cardiovascular Risk PredictionFriday 29th August, 08:15am – 09:45am (CEST… View more